Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475675 | 0.90 | TSHR (0.59) | GRM5SMN1; SMN2LMNAFFAR4TSHR | |
| SCHEMBL4466412 | 0.89 | CYP11B1 (0.56) | GRM5SMN1; SMN2LMNAFFAR4ALDH1A1 | |
| SCHEMBL12412646 | 0.88 | GRM5 (0.77) | GRM5KMT2A | |
| SCHEMBL12412147 | 0.88 | GRM5 (0.61) | GRM5SMN1; SMN2LMNATSHRALDH1A1 | |
| SCHEMBL12830278 | 0.88 | GRM5 (0.58) | GRM5SMN1; SMN2LMNAFFAR4TSHR | |
| SCHEMBL12412157 | 0.85 | GRM5 (0.63) | GRM5SMN1; SMN2LMNAFFAR4 | |
| SCHEMBL1486159 | 0.85 | GRM5 (0.78) | GRM5SMN1; SMN2LMNA | |
| SCHEMBL12412623 | 0.82 | GRM5 (0.64) | GRM5SMN1; SMN2LMNATSHRALDH1A1 | |
| SCHEMBL4478243 | 0.80 | CYP11B1 (0.60) | GRM5SMN1; SMN2LMNATSHRALDH1A1 | |
| SCHEMBL12412722 | 0.80 | GRM5 (0.60) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | claimed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | claimed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | claimed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | claimed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | claimed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | claimed |
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158233-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | GRM5 2825/4885SMN1; SMN2 633/4885LMNA 228/4885 |
| US-20060173024-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | GRM5 2825/4885SMN1; SMN2 633/4885LMNA 228/4885 |
| US-20050148638-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | GRM5 2825/4885SMN1; SMN2 633/4885LMNA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.